Advertisement

Meropenem antimicrobial stewardship program: clinical, economic, and antibiotic resistance impact

  • J. F. García-RodríguezEmail author
  • B. Bardán-García
  • M. F. Peña-Rodríguez
  • H. Álvarez-Díaz
  • A. Mariño-Callejo
Original Article

Abstract

There are few prospective studies with sufficient duration in time to evaluate clinical and antibiotic resistance impact of antibiotic stewardship programs (ASP). This is a descriptive study between January 2012 and December 2017, pre-post intervention. A meropenem ASP was initiated in January 2015; in patients who started treatment with meropenem, an infectious disease physician performed treatment recommendations to prescribers. Prospective information was collected to evaluate adequacy of meropenem prescription to local guidelines and to compare results between cases with accepted or rejected intervention. Analysis was performed to verify variables associated with intervention acceptance and with any significant change in meropenem consumption, hospital-acquired multidrug-resistant (MDR) bloodstream infections (BSIs), and 30-day all-cause crude death in MDR BSIs. Adequacy of meropenem prescription and de-escalation from meropenem treatment to narrower-spectrum antibiotic improved progressively over time, after ASP implementation (p < 0.001). Interventions on prescription were performed in 330 (38.7%) patients without meropenem justified treatment; in 269, intervention was accepted and in 61 not. Intervention acceptance was associated with shorter duration of treatment, cost, and inpatient days (p < 0.05); intervention rejection was not associated with severity of patient. During the period 2015–2017, meropenem consumption decreased compared with 2012–2014 (rate ratio [RR] 0.67; 95% CI 0.58–0.77, p < 0.001). Also decreased were hospital-acquired MDR BSI rate (RR 0.63; 95% CI 0.38–1.02, p = 0,048) and 30-day all-cause crude death in MDR BSIs (RR 0.45; 95% CI 0.14–1.24, p = 0.096), coinciding in time with ASP start-up. The decrease and better use of meropenem achieved had a sustained clinical, economic, and ecological impact, reducing costs and mortality of hospital-acquired MDR BSIs.

Keywords

Antimicrobial stewardship Multidrug-resistant Hospital infections Bloodstream infections Carbapenems 

Notes

Acknowledgments

The authors acknowledge the Clinical Epidemiology and Biostatistics Unit of the Complejo Hospitalario Universitario A Coruña and the Spanish Platform for Clinical Research and Clinical Trials, SCReN (Spanish Clinical Research Network), for their assistance in methodological design and statistical analysis.

Compliance with ethical standards

Competing interests

The authors declare that they have no competing interests.

References

  1. 1.
    United Nations (2017) General Assembly of the United Nations: President of the 71st Session. 2016. http://www.un.org/pga/71/2016/09/21/press-release-hl-meeting-on-antimicrobial-resistance/ (accesed Nov 21, 2007)
  2. 2.
    Barlam TF, Cosgrove SE, Abbo LM, MacDougall C, Schuetz AN, Septimus EJ et al (2016) Implementing an antibiotic stewardship program: guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. Clin Infect Dis 62(10):e51–e77CrossRefGoogle Scholar
  3. 3.
    Karanika S, Paudel S, Grigoras C, Kalbasi A, Mylonakis E (2016) Systematic review and meta-analysis of clinical and economic outcomes from the implementation of hospital-based antimicrobial stewardship programs. Antimicrob Agents Chemother 60:4840–4852CrossRefGoogle Scholar
  4. 4.
    ECDC (2017) Summary of the latest data on antibiotic consumption in the European Union. https://ecdc.europa.eu/sites/portal/files/documents/Final_2017_EAAD_ESAC-Net_Summary-edited%20-%20FINALwith%20erratum.pdf. (accessed Feb 28, 2018)
  5. 5.
    Schuts EC, Hulscher ME, Mouton JW, Verduin CM, Stuart JWTC, Overdiek HWPM et al (2016) Current evidence on hospital antimicrobial stewardship objectives: a systematic review and meta-analysis. Lancet Infect Dis 16:847–856CrossRefGoogle Scholar
  6. 6.
    Lawes T, López-Lozano JM, Nebot CA, Macartney G, Subbarao-Sharma R, Dare CRJ et al (2015) Effects of national antibiotic stewardship and infection control strategies on hospital-associated and community-associated meticillin-resistant Staphylococcus aureus infections across a region of Scotland: a non-linear time-series study. Lancet Infect Dis 15:1438–1449CrossRefGoogle Scholar
  7. 7.
    Akpan MR, Ahmad R, Shebl NA, Ashiru-Oredope D (2016) A review of quality measures for assessing the impact of antimicrobial stewardship programs in hospitals. Antibiotics 5(1):5.  https://doi.org/10.3390/antibiotics5010005
  8. 8.
    Molina J, Peñalva G, Gil-Navarro MV, Praena J, Lepe JA, Pérez-Moreno MA et al (2017) Long-term impact of an educational antimicrobial stewardship program on hospital-acquired candidemia and multidrug-resistant bloodstream infections: a quasi-experimental study of interrupted time-series analysis. Clin Infect Dis 65(12):1992–1999Google Scholar
  9. 9.
    Feazel LM, Malhotra A, Perencevich EN, Kaboli P, Diekema DJ, Schweizer ML (2014) Effect of antibiotic stewardship programmes on Clostridium difficile incidence: a systematic review and meta-analysis. J Antimicrob Chemother 69:148–154CrossRefGoogle Scholar
  10. 10.
    Davey P, Marwick CA, Scott CL, Charani E, McNeil K, Brown E et al (2017) Interventions to improve antibiotic prescribing practices for hospital inpatients. Cochrane Database Syst Rev 2:CD003543.  https://doi.org/10.1002/14651858.CD003543.pub4 Google Scholar
  11. 11.
    Baur D, Gladstone BP, Burkert F, Carrara E, Foschi F, Döbele S, Tacconelli E (2017) Effect of antibiotic stewardship on the incidence of infection and colonisation with antibiotic-resistant bacteria and Clostridium difficile infection: a systematic review and meta-analysis. Lancet Infect Dis 17(9):990–1001CrossRefGoogle Scholar
  12. 12.
    García-Rodríguez JF, Álvarez-Díaz H, Vilariño-Maneiro L, Lorenzo-García MV, Cantón-Blanco A, Ordoñez-Barrosa P et al (2013) Epidemiology and impact of a multifaceted approach in controlling central venous catheter associated blood stream infections outside the intensive care unit. BMC Infect Dis 13:445 http://www.biomedcentral.com/1471-2334/13/445. (Accessed Feb 8, 2018CrossRefGoogle Scholar
  13. 13.
    Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM et al (2013) Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 41(2):580–637CrossRefGoogle Scholar
  14. 14.
    WHO Collaborating Center for Drug Statistics Methodology (2016). DDD definition and general considerations.. Available from: https://www.whocc.no/ddd/definition_and_general_considera/. (Accessed Feb 8, 2018)
  15. 15.
    Mattner F, Bange FC, Meyer E, Seifert H, Wichelhaus TA, Chaberny IF (2012) Preventing the spread of multidrug-resistant gram-negative pathogens: recommendations of an expert panel of the German Society For Hygiene and Microbiology. Dtsch Arztebl Int 109(3):39–45Google Scholar
  16. 16.
    Mendez CM, Harrington DW, Christenson P, Spelberg B (2014) Impact of hospital variables on case mix index as a marker of diseases severity. Popul Health Manag 17:28–34CrossRefGoogle Scholar
  17. 17.
    Moehring RW, Anderson DJ, Cochran RL, Hicks LA, Srinivasan A, Ashley ESD (2017) For the Structured Taskforce of Experts Working at Reliable Standards for Stewardship (STEWARDS) Panel. Expert consensus on metrics to assess the impact of patient-level antimicrobial stewardship interventions in acute-care settings. Clin Infect Dis 64(3):377–383CrossRefGoogle Scholar
  18. 18.
    Spivak ES, Cosgrove SE, Srinivasan A (2016) Measuring appropriate antimicrobial use: attempts at opening the black box. Clin Infect Dis 63(12):1639–1644CrossRefGoogle Scholar
  19. 19.
    Gums J, Yancey R, Hmilton C, Kubilis PA (1999) A randomized, prospective study measuring outcomes after antibiotic therapy intervention by a multidisciplinary consult team. Pharmacotherapy 19:1369–1377CrossRefGoogle Scholar
  20. 20.
    Ng CK, Wu TC, Chan WMJ, Leung YSN, Pli CK, Tsang DNC, Leung GM (2008) Clinical and economic impact of an antibiotics steweardship programme in a regional hospital in Hong Kong. Qual Saf Health Care 17:387–392CrossRefGoogle Scholar
  21. 21.
    Chan Y, Lin T, Huang C, Deng S, Wu T, Lue H, Chiu C (2011) Implementation and outcomes of a hospital-wide computerised antimicrobial stewardship program in a large medical centre in Taiwan. J Antimicrob Agents 38:486–492CrossRefGoogle Scholar
  22. 22.
    Liew Y, Lee W, Loh J, Cai Y, Tang S, Lim C et al (2012) Impact of an antimicrobial stewardship program on patient safety in Singapore General Hospital. Int J Antimicrob Agents 40:55–60CrossRefGoogle Scholar
  23. 23.
    Díaz-Granados C (2012) Prospective audit for antimicrobial stewardship in intensive care: impact on resistance and clinical outcomes. Am J Infect Control 40:526–529CrossRefGoogle Scholar
  24. 24.
    Lin Y, Lin I, Yen F, Lin P, Shiu Y, Hu H, Yang Y (2013) Impact of an antimicrobial stewardship program with multidisciplinary cooperation in a community public teaching hospital in Taiwan. Am J Infect Control 41:1069–1072CrossRefGoogle Scholar
  25. 25.
    Rosa R, Goldani L, dos Santos R (2014) Association between adherence to an antimicrobial stewardship program and mortality among hospitalised cancer patients with febrile neutropaenia: a prospective cohort study. BMC Infect Dis 14:286CrossRefGoogle Scholar
  26. 26.
    Tedeschi S, Trapani F, Giannella M, Cristini F, Tumietto F, Bartoletti M et al (2017) An antimicrobial stewardship program based on systematic infectious disease consultation in a rehabilitation facility. Infect Control Hosp Epidemiol 38:76–82CrossRefGoogle Scholar
  27. 27.
    Lew K, Ng T, Tan M, Tan S, Lew E, Ling L et al (2015) Safety and clinical outcomes of carbapenem de-escalation as part of an antimicrobial stewardship program in an ESBL-endemic setting. J Antimicrob Chemother 70:1219–1225Google Scholar
  28. 28.
    Teng CB, Ng TM, Tan MW, Tan SH, Tay M, Lim SF et al (2015) Safety and effectiveness of improving carbapenem use via prospective review and feedback in a multidisciplinary antimicrobial stewardship programme. Ann Acad Med Singap 44(1):19–25Google Scholar
  29. 29.
    Giacobbe DR, Del Bono V, Mikulska M, Gustinetti G, Marchese A, Mina F et al (2017) Impact of a mixed educational and semi-restrictive antimicrobial stewardship project in a large teaching hospital in Northern Italy. Infection 45(6):849–856CrossRefGoogle Scholar
  30. 30.
    McCarty TP, Pappas PG (2016) Invasive candidiasis. Infect Dis Clin N Am 30(1):103–124CrossRefGoogle Scholar
  31. 31.
    Vena A, Bouza E, Valerio M, Padilla B, Paño-Pardo JR, Fernández-Ruiz M et al (2017) Candidemia in non-ICU surgical wards: comparison with medical wards. PLoS One 12(10):e0185339CrossRefGoogle Scholar
  32. 32.
    Lortholary O, Renaudat C, Sitbon K, Desnos-Ollivier M, Bretagne S, Dromer F (2017) French Mycoses Study Group. The risk and clinical outcome of candidemia depending on underlying malignancy. Intensive Care 43(5):652–662CrossRefGoogle Scholar
  33. 33.
    Stenehjem E, Hyun DY, Yu KC, Meyer M, Raj D, Srinivasan A (2017) Antibiotic stewardship in small hospitals: barriers and potential solutions. Clin Infect Dis 65(4):691–696CrossRefGoogle Scholar
  34. 34.
    Apisarnthanarak A, Bhooanusas N, Yaprasert A, Mundy LM (2013) Carbapenem de-escalation therapy in a resource-limited setting. Infect Control Hosp Epidemiol 34(12):1310–1313CrossRefGoogle Scholar
  35. 35.
    Davey P, Brown E, Charani E, Fenelon L, Gould IM, Holmes A et al (2013) Interventions to improve antibiotic prescribing practices for hospital inpatients. Cochrane Database Syst Rev (4):CD003543.  https://doi.org/10.1002/14651858.CD003543.pub3
  36. 36.
    Cosgrove SE, Hermsen ED, Rybak MJ, File T, Parker SK, Barlam TF (2014) Guidance for the knowledge and skills required for antimicrobial stewardship leaders. Infect Control Hosp Epidemiol 35(12):1444–1451CrossRefGoogle Scholar
  37. 37.
    Burnham JP, Olsen MA, Stwalley D, Kwon JH, Babcock HM, Kollef MH (2018) Infectious diseases consultation reduces 30-day and 1-year all-cause mortality for multidrug-resistant organism infections. Open Forum Infect Dis 5(3):ofy026.  https://doi.org/10.1093/ofid/ofy026 CrossRefGoogle Scholar
  38. 38.
    Seah VXF, Ong RYL, Lim ASY, Chong CY, Tan NWH, Thoon KC (2017) Impact of a carbapenem antimicrobial stewardship program on patient outcomes. Antimicrob Agents Chemother 61(9):e00736-17.  https://doi.org/10.1128/AAC.00736-17
  39. 39.
    Robson SE, Cockburn A, Sneddon J, Mohana A, Bennie M, Mullen AB et al (2018) Optimizing carbapenem use through a national quality improvement programme. J Antimicrob Chemother 73(8):2223–2230.  https://doi.org/10.1093/jac/dky171
  40. 40.
    Doron S, Davidson LE (2011) Antimicrobial stewardship. Mayo Clin Proc 86:1113–1123CrossRefGoogle Scholar
  41. 41.
    Pulcini C, Morel CM, Tacconelli E, Beovic B, de With K, Goossens H et al (2017) Human resources estimates and funding for antibiotic stewardship teams are urgently needed. Clin Microbiol Infect 23(11):785–787CrossRefGoogle Scholar
  42. 42.
    Katz MJ, Gurses AP, Tamma PD, Cosgrove SE, Miller MA, Jump RLP (2017) Implementing antimicrobial stewardship in long-term care settings: an integrative review using a human factors approach. Clin Infect Dis 65(11):1943–1951CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Infectious Diseases Unit. Department of Internal MedicineUniversity Hospital of FerrolLa CoruñaSpain
  2. 2.Department of PharmacyUniversity Hospital of FerrolLa CoruñaSpain
  3. 3.Department of MicrobiologyUniversity Hospital of FerrolLa CoruñaSpain

Personalised recommendations